JP2015529633A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529633A5
JP2015529633A5 JP2015517672A JP2015517672A JP2015529633A5 JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5 JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5
Authority
JP
Japan
Prior art keywords
bag3
biological sample
antibody
urine
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529633A (ja
JP6654432B2 (ja
Filing date
Publication date
Priority claimed from EP12172531.1A external-priority patent/EP2676966A1/en
Application filed filed Critical
Publication of JP2015529633A publication Critical patent/JP2015529633A/ja
Publication of JP2015529633A5 publication Critical patent/JP2015529633A5/ja
Application granted granted Critical
Publication of JP6654432B2 publication Critical patent/JP6654432B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517672A 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3 Expired - Fee Related JP6654432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12172531.1 2012-06-19
EP12172531.1A EP2676966A1 (en) 2012-06-19 2012-06-19 BAG3 as biochemical serum and tissue marker
PCT/EP2013/061976 WO2013189778A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Publications (3)

Publication Number Publication Date
JP2015529633A JP2015529633A (ja) 2015-10-08
JP2015529633A5 true JP2015529633A5 (enExample) 2016-07-28
JP6654432B2 JP6654432B2 (ja) 2020-02-26

Family

ID=48607259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517672A Expired - Fee Related JP6654432B2 (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3
JP2015517669A Pending JP2015521475A (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015517669A Pending JP2015521475A (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3

Country Status (12)

Country Link
US (2) US20150132764A1 (enExample)
EP (3) EP2676966A1 (enExample)
JP (2) JP6654432B2 (enExample)
KR (2) KR20150036102A (enExample)
CN (2) CN104507965B (enExample)
AU (2) AU2013279604B2 (enExample)
BR (2) BR112014031958A2 (enExample)
CA (2) CA2876872A1 (enExample)
ES (1) ES2795981T3 (enExample)
IN (2) IN2014DN10562A (enExample)
PL (1) PL2861618T3 (enExample)
WO (2) WO2013189778A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130403A1 (it) 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN113862361B (zh) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
AU5789500A (en) * 1999-07-09 2001-01-30 Burnham Institute, The A method for determining the prognosis of cancer patients by measuring levels ofbag expression
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
WO2011044927A1 (en) * 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the diagnosis or prognosis of an advanced heart failure
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
GB201017520D0 (en) * 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers

Similar Documents

Publication Publication Date Title
JP2015529633A5 (enExample)
Wu Release of cardiac troponin from healthy and damaged myocardium
Aulin et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation
Jia et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography
Shere et al. Circulating blood biomarkers in essential hypertension: a literature review
HK1202154A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
FI3356827T3 (fi) GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
Gruden et al. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma
CA2509063A1 (en) Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
RU2013106940A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
Wen et al. Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease
WO2014167969A1 (ja) 大腸がんの検出方法
Cardinale et al. Role of biomarkers in cardioncology.
Villacorta et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure
Ochiumi et al. Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation
Schmid et al. ST2 predicts survival in patients undergoing transcatheter aortic valve implantation
Hiwasa Association of serum antibody levels against TUBB2C with diabetes and cerebral infarction
JP6431373B2 (ja) 女性の対象が心臓血管事象に罹患するリスクを予測する方法
FI3356826T3 (fi) Gdf-15 melanooman diagnostisena markkerina
RU2670052C1 (ru) Антигенный полипептид для выявления в плазме крови иммунного маркера - аутоантитела к vegfr1 и его применение
CN107255711B (zh) 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途
CN105445471A (zh) 心血管疾病标记物palm及利用其的心血管疾病诊断方法